122 related articles for article (PubMed ID: 9157949)
21. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
[TBL] [Abstract][Full Text] [Related]
22. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.
Smit M; de Knijff P; van der Kooij-Meijs E; Groenendijk C; van den Maagdenberg AM; Gevers Leuven JA; Stalenhoef AF; Stuyt PM; Frants RR; Havekes LM
J Lipid Res; 1990 Jan; 31(1):45-53. PubMed ID: 2313204
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia.
Hoffmann MM; Scharnagl H; Köster W; Winkler K; Wieland H; März W
Clin Chim Acta; 2001 Jan; 303(1-2):41-8. PubMed ID: 11163021
[TBL] [Abstract][Full Text] [Related]
24. Doubling expression of the low density lipoprotein receptor by truncation of the 3'-untranslated region sequence ameliorates type iii hyperlipoproteinemia in mice expressing the human apoe2 isoform.
Knouff C; Malloy S; Wilder J; Altenburg MK; Maeda N
J Biol Chem; 2001 Feb; 276(6):3856-62. PubMed ID: 11076954
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.
Mahley RW; Huang Y; Rall SC
J Lipid Res; 1999 Nov; 40(11):1933-49. PubMed ID: 10552997
[TBL] [Abstract][Full Text] [Related]
27. Identification, molecular characterization, and cellular studies of an apolipoprotein E mutant (E1) in three unrelated families with hyperlipidemia.
Miller DB; Hegele RA; Wolfe BM; Huff MW
J Clin Endocrinol Metab; 1995 Mar; 80(3):807-13. PubMed ID: 7883834
[TBL] [Abstract][Full Text] [Related]
28. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies.
Pocovi M; Cenarro A; Civeira F; Myers RH; Casao E; Esteban M; Ordovas JM
Atherosclerosis; 1996 Apr; 122(1):33-46. PubMed ID: 8724110
[TBL] [Abstract][Full Text] [Related]
29. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.
Mann WA; Gregg RE; Sprecher DL; Brewer HB
Biochim Biophys Acta; 1989 Oct; 1005(3):239-44. PubMed ID: 2804053
[TBL] [Abstract][Full Text] [Related]
30. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein E2/E2 genotype in combination with mutations in the LDL receptor gene causes type III hyperlipoproteinemia.
Geisel J; Bunte T; Bodis M; Oette K; Herrmann W
Clin Chem Lab Med; 2002 May; 40(5):475-9. PubMed ID: 12113291
[TBL] [Abstract][Full Text] [Related]
32. Compound heterozygote for both rare apolipoprotein E1 (Gly127-->Asp, Arg158-->Cys) and E3(Cys112-->Arg, Arg251-->Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia.
Richard P; Beucler I; Pascual De Zulueta M; Biteau N; De Gennes JL; Iron A
Clin Sci (Lond); 1997 Jul; 93(1):89-95. PubMed ID: 9279208
[TBL] [Abstract][Full Text] [Related]
33. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
35. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
Saito M; Eto M; Kaku K
Metabolism; 2002 Aug; 51(8):964-9. PubMed ID: 12145767
[TBL] [Abstract][Full Text] [Related]
36. Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158-->Cys) compared.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Van der Laarse A; Van 't Hooft FM
Clin Chem; 1994 Aug; 40(8):1559-66. PubMed ID: 8044997
[TBL] [Abstract][Full Text] [Related]
37. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
[TBL] [Abstract][Full Text] [Related]
38. Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia.
Sakuma N; Hibino T; Saeki T; Nagata T; Sato T; Okuda N; Matsunaga A; Sasaki J
J Atheroscler Thromb; 2014; 21(9):983-8. PubMed ID: 24953047
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects.
Ikewaki K; Zech LA; Brewer HB; Rader DJ
J Lab Clin Med; 2002 Nov; 140(5):369-74. PubMed ID: 12434139
[TBL] [Abstract][Full Text] [Related]
40. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
